Tumor necrosis factor

Tumor necrosis factor (TNF) is a multifunctional cytokine and a central mediator of inflammation, immunity, and cellular homeostasis. First identified in 1975 as a serum factor that causes necrosis of tumors in infected animals, TNF is now understood as a primary signaling molecule in the neuro-immune axis, with profound effects on the brain, metabolism, and behavior.

TNF exists in two biologically active forms: TNF-α, the primary inflammatory cytokine, and TNF-β (lymphotoxin), which plays a role in lymphoid organ development. TNF-α is produced mainly by macrophages, monocytes, and T cells in response to infection, injury, and stress. It signals through two receptors — TNFR1 and TNFR2 — which activate divergent downstream pathways including NF-κB, MAPK, and death receptor cascades.

In the immune system, TNF-α orchestrates the acute inflammatory response: it induces fever, recruits neutrophils to sites of infection, and stimulates the production of other cytokines including interleukin-1 and interleukin-6. Dysregulated TNF-α signaling is the pathological mechanism underlying rheumatoid arthritis, inflammatory bowel disease, and psoriasis — conditions for which TNF inhibitors (such as infliximab and adalimumab) are now standard therapy.

In the nervous system, TNF-α is produced by microglia and astrocytes and acts as a neuromodulator. It regulates synaptic scaling — the homeostatic adjustment of synaptic strength — and plays a role in synaptic plasticity, learning, and memory. Chronic elevation of brain TNF-α is associated with neurodegeneration, depression, and cognitive impairment. TNF-α contributes to allostatic load by sustaining inflammatory signaling in the brain and periphery during chronic stress.

TNF-α is also a mediator of sleep homeostasis. Administration of TNF-α increases sleep duration and intensity, while TNF-α knockout mice show reduced sleep responses to sleep deprivation. The cytokine operates in a bidirectional feedback loop with sleep: sleep deprivation elevates TNF-α, and elevated TNF-α promotes sleep. This loop is one of the molecular mechanisms linking immune activation to sleep regulation.

The therapeutic revolution of TNF inhibition has an unexpected psychiatric dimension. Patients receiving anti-TNF therapy for autoimmune disease frequently report improvements in mood and fatigue that precede changes in their somatic symptoms — suggesting that TNF-α is not merely a marker of inflammation but a causal factor in the cytokine-mediated pathway to depression.